AMPAR autoimmunity: Neurological and oncological accompaniments and co-existing neural autoantibodies

α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) encephalitis is rare but treatable. We reviewed the clinical and autoantibody profiles of 52 AMPAR-IgG-positive patients (median age 48 years [range 12–81]; 38 female) identified at the Mayo Clinic neuroimmunology laborator y. Main presentation was encephalitis; symptoms other than encephalitis associated with co-existing antibodies (p = 0.004). A tumor was found in 33/44; mostly thymoma. Most patients had partial (14/29) or complete (11/29) immunotherapy response.

Source: Journal of Neuroimmunology - December 23, 2022 Category: Allergy & Immunology Authors: Jennifer A. McCombe, Cecilia Zivelonghi, Nisa Vorasoot, Masoud Majed, Eoin P. Flanagan, Divyanshu Dubey, Sean J. Pittock, Andrew McKeon, Anastasia Zekeridou Tags: Short Communication Source Type: research